EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Sodium and Potassium Changes During Decongestion with Acetazolamide – A Pre-Specified Analysis from the ADVOR Trial

Sebastiaan Dhont iD, Pieter Martens, Evelyne Meekers, Jeroen Dauw, Frederik H Verbrugge, Petra Nijst, Jozine M Ter Maaten, Kevin Damman, Alexandre Mebazaa, Gerasimos Filippatos, Frank Ruschitzka, W H Wilson Tang und 2 weitere

European Journal of Heart Failure · 2023

DOI: 10.1002/ejhf.2863 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Heart Failure, 2023. Verfasst von Sebastiaan Dhont und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Ziekenhuis Oost-Limburg A.V, Genk, Belgium. Hauptthemen laut MEDLINE: Heart Failure, Hyponatremia, Hypokalemia. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Belgian Health Care Knowledge Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Acetazolamide, an inhibitor of proximal tubular sodium reabsorption, leads to more effective decongestion in acute heart failure (AHF). It is unknown whether acetazolamide alters serum sodium and potassium levels on top of loop diuretics and if baseline values modify the treatment effect of acetazolamide. Methods and results This is a pre-specified sub-analysis of the ADVOR trial that randomized 519 patients with AHF and volume overload in a 1:1 ratio to intravenous acetazolamide or matching placebo on top of standardized intravenous loop diuretics. Mean potassium and sodium levels at randomization were 4.2 ± 0.6 and 139 ± 4 mmol/L in the acetazolamide arm versus 4.2 ± 0.6 and 140 ± 4 mmol/L in the placebo arm. Hypokalaemia (<3.5 mmol/L) on admission was present in 44 (9%) patients and hyponatraemia (≤135 mmol/L) in 82 (16%) patients. After 3 days of treatment, 44 (17%) patients in the acetazolamide arm and 35 (14%) patients in the placebo arm developed hyponatraemia (p = 0.255). Patients randomized to acetazolamide demonstrated a slight decrease in mean potassium levels during decongestion, which was non-significant over time (p = 0.053) and had no significant impact on hypokalaemia incidence (p = 0.061). Severe hypokalaemia (<3.0 mmol/L) occurred in only 7 (1%) patients, similarly distributed between the two treatment arms (p = 0.676). Randomization towards acetazolamide improved decongestive response irrespective of baseline serum sodium and potassium levels.

Conclusions

Acetazolamide on top of standardized loop diuretic therapy does not lead to clinically important hypokalaemia or hyponatraemia and improves decongestion over the entire range of baseline serum potassium and sodium levels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureHyponatremiaHypokalemiaHumansAcetazolamideSodiumSodium Potassium Chloride Symporter InhibitorsPotassiumDiuretics

Stichwörter der Autor:innen

AcetazolamideAcute heart failureDecongestionHypokalaemiaHyponatraemia

Substanzen

AcetazolamideSodiumSodium Potassium Chloride Symporter InhibitorsPotassiumDiuretics

Autor:innen und Institutionen

  • Department of Cardiology, Ziekenhuis Oost-Limburg A.V, Genk, Belgium.
  • Hasselt University, Diepenbeek/Hasselt, Belgium.
  • Department of Cardiovascular Medicine, Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Department of Cardiology, AZ Sint-Lucas, Ghent, Belgium.
  • Centre for Cardiovascular Diseases, University Hospital Brussels, Jette, Belgium.
  • Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Jette, Belgium.

ORCID-Profile: Sebastiaan Dhont

Förderung

  • Belgian Health Care Knowledge Centre

Zitieren

APA

Dhont, S., Martens, P., Meekers, E., Dauw, J., Verbrugge, F. H., Nijst, P., Ter Maaten, J. M., Damman, K., Mebazaa, A., Filippatos, G., Ruschitzka, F., Tang, W. H. W., Dupont, M., & Mullens, W. (2023). Sodium and Potassium Changes During Decongestion with Acetazolamide – A Pre-Specified Analysis from the ADVOR Trial. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.2863

Vancouver

Dhont S, Martens P, Meekers E, Dauw J, Verbrugge FH, Nijst P, et al. Sodium and Potassium Changes During Decongestion with Acetazolamide – A Pre-Specified Analysis from the ADVOR Trial. European Journal of Heart Failure. 2023. doi:10.1002/ejhf.2863

BibTeX
@article{Dhont2023,
  author = {Dhont, Sebastiaan and Martens, Pieter and Meekers, Evelyne and Dauw, Jeroen and Verbrugge, Frederik H and Nijst, Petra and Ter Maaten, Jozine M and Damman, Kevin and Mebazaa, Alexandre and Filippatos, Gerasimos and Ruschitzka, Frank and Tang, W H Wilson and Dupont, Matthias and Mullens, Wilfried},
  title = {Sodium and Potassium Changes During Decongestion with Acetazolamide – A Pre-Specified Analysis from the ADVOR Trial},
  journal = {European Journal of Heart Failure},
  year = {2023},
  doi = {10.1002/ejhf.2863}
}
Kostenlos starten →